Cargando…

CHEK2 mutations as markers for high risk of breast cancer

Detalles Bibliográficos
Autores principales:	Cybulski, Cezary, Wokołorczyk, Dominika, Jakubowska, Anna, Huzarski, Tomasz, Byrski, Tomasz, Gronwald, Jacek, Dębniak, Tadeusz, Górski, Bohdan, Blecharz, P, Narod, S A, Lubiński, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395391/ http://dx.doi.org/10.1186/1897-4287-10-S3-A4

Ejemplares similares

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Coverage of the Genetic Background of Breast Cancer in the Polish Population
por: Serrano-Fernández, Pablo, et al.
Publicado: (2006)

Magnesium as a diagnostic marker of cancer
por: Marciniak, Wojciech, et al.
Publicado: (2015)

Selenium as diagnostic marker of cancers
por: Jaworska-Bieniek, Katarzyna, et al.
Publicado: (2015)

Zinc as diagnostic marker of cancers
por: Kaczmarek, Katarzyna, et al.
Publicado: (2015)

Iron as diagnostic marker of cancer
por: Sukiennicki, Grzegorz, et al.
Publicado: (2015)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Iron and breast cancer risk
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

The CHEK 2 GENE mutations and the risk of Gastric cancer
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation
por: Suszynska, Malwina, et al.
Publicado: (2019)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
por: Gliniewicz, Katarzyna, et al.
Publicado: (2023)

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families
por: Dębniak, Tadeusz, et al.
Publicado: (2015)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

Risk of Second Primary Thyroid Cancer in Women with Breast Cancer
por: Cieszyńska, Monika, et al.
Publicado: (2022)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland
por: Gronwald, Jacek, et al.
Publicado: (2006)

Selenium (Se) and breast cancer risk
por: Jaworska - Bieniek, Katarzyna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s9hmc47afi6r6aknd1f1u9t00u